LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations

Keyphrases

• Chronic Phase 100%
• JAK2 mutation 100%
• Blast Phase Myeloproliferative Neoplasm 100%
• MPL mutation 100%
• IDH mutation 100%
• Mutation Study 100%
• TET2 mutation 100%
• Blast Phase 80%
• Exon 2 60%
• Codon 40%
• Myeloproliferative Neoplasms 40%
• Pleckstrin Homology Domain 40%
• Sample Analysis 40%
• JAK2V617F 40%
• Primary Myelofibrosis 40%
• Exon 5 20%
• Missense mutation 20%
• Mutation Analysis 20%
• Polycythemia Vera 20%
• Synonymous mutation 20%
• Mutually Exclusive 20%
• Essential Thrombocythemia 20%
• Deletion mutation 20%
• Phase-only 20%
• Tet Methylcytosine Dioxygenase 2 20%
• Post-primary 20%

Biochemistry, Genetics and Molecular Biology

• Exon 100%
• Janus Kinase 100%
• Codon 50%
• Pleckstrin Homology Domain 50%
• Missense Mutation 25%
• Essential Thrombocythaemia 25%